From: Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
Liver metastases (N) | Dose (Gy × fr) | Median follow up (mos) | Actuarial LC rate (%) | ||
---|---|---|---|---|---|
at 12 mos | at 24 mos | ||||
Herfarth et al. 2001 [40] | 56 | 14-26 × 1 | 6 | 75 | |
Wulf et al. 2001 [41] | 23 | 30 × 3 | 9 | 76 | 61 |
Wulf et al. 2006 [42]. | 51 | variable dose × (1–3) | 15 | 92 | 66 |
Hoyer et al. 2006 [43] | 97/141*lesions | 45 × 3 | 4.3 years | 79 | |
Méndez-Romero et al. 2006 [44] | 34 | 37.5 × 3 | 13 | 100 | 86 |
Kavanagh et al. 2006 [45]. | 36 | 60 × 3 | 19 | 93 (at 18 mos) | |
Milano et al. 2008 [46]. | 120/293*lesions | 50 × 5 | 41 | 67 | |
Rusthoven et al. 2009 [47]. | 63 | 36 - 60 × 3 | 16 | 95 | 92 |
Van der Pool et al. 2010 [48] | 31 | 37.5 - 45 × 3 | 26 | 100 | 74 |
Rule et al. 2010 [49]. | 37 | 30 × 3 | 20 | 56 | |
50 × 5 | 89 | ||||
60 × 5 | 100 |